Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.41 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20565600 | 1.00 | CD274 (0.41) | CD274PDCD1LG2PDCD1TRPV3LMNA | |
| SCHEMBL29385422 | 1.00 | CD274 (0.41) | CD274PDCD1LG2PDCD1TRPV3LMNA | |
| SCHEMBL17748267 | 0.73 | CD274 (0.38) | CD274PDCD1LG2PDCD1LMNA | |
| SCHEMBL16196324 | 0.73 | PDXK (0.34) | — | |
| SCHEMBL16196135 | 0.70 | — | — | |
| SCHEMBL22004565 | 0.69 | SLC6A2 (0.32) | — | |
| SCHEMBL20564959 | 0.69 | TRPV3 (0.31) | TRPV3 | |
| SCHEMBL29383550 | 0.69 | TRPV3 (0.31) | TRPV3 | |
| SCHEMBL21800566 | 0.68 | — | — | |
| SCHEMBL31260022 | 0.68 | CYP11B2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2025-01-09 | — | — | US | disclosed |
| US-12129263-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| CN-110913858-A | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2020-03-24 | — | — | CN | disclosed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | CD274 2204/4885PDCD1LG2 1313/4885PDCD1 1175/4885 |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | CD274 2204/4885PDCD1LG2 1313/4885PDCD1 1175/4885 |
| US-11203600-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | CD274 2204/4885PDCD1LG2 1313/4885PDCD1 1175/4885 |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | CD274 2204/4885PDCD1LG2 1313/4885PDCD1 1175/4885 |
| US-12129263-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | CD274 2204/4885PDCD1LG2 1313/4885PDCD1 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.